Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.
Wentao TianLishui NiuRongrong ZhouZiqi WangJiaoyang NingRuoyu LuYin ShiZhaohua TanPublished in: Cancer medicine (2024)
From the perspective of the United States health care system, osimertinib plus chemotherapy is not cost-effective compared to osimertinib alone for treatment-naïve patients with EGFR-mutated advanced NSCLC, but more favorable cost-effectiveness occurs in patients with L858R mutations and patients without baseline CNS metastases.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- small cell lung cancer
- tyrosine kinase
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- locally advanced
- peritoneal dialysis
- blood brain barrier
- prognostic factors
- patient reported outcomes
- squamous cell carcinoma
- radiation therapy
- chemotherapy induced
- rectal cancer